PMID- 11070154
OWN - NLM
STAT- MEDLINE
DCOM- 20010118
LR  - 20220317
IS  - 1084-8592 (Print)
IS  - 1084-8592 (Linking)
VI  - 5
IP  - 3
DP  - 2000 Sep
TI  - HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in 
      situ hybridization: comparison of results and correlation with survival.
PG  - 199-207
AB  - BACKGROUND: HER-2/neu immunohistochemistry (IHC) and fluorescence in situ 
      hybridization (FISH) results guide breast cancer therapy; however, few studies 
      compared the results and no published studies have correlated them with patient 
      outcome. METHODS AND RESULTS: We compared results, cost, and turnaround time in 
      117 archival, invasive breast carcinomas and compared 50-month survival in 65 of 
      these cases using commercial HER-2/neu IHC and FISH assays. Twenty-one of 112 
      FISH (19%) and 33 of 117 IHC cases (28%) were positive. Concordance was high 
      overall (88%; 98 of 112 cases) and in IHC 3+ cases (88%; 14 of 16 cases) but low 
      in IHC 2+ cases (35%; six of 17 cases). Survival correlated with IHC results in 
      3+ cases (P =.02) and FISH cases with signal ratio greater than 4.0 (P =.03), but 
      not in IHC 2+ cases (P=.7). Cost and turnaround time were greater for FISH. 
      CONCLUSION: IHC is appropriate for initial HER-2/neu assessment; however, 
      patients with tumors scored less than 3+, particularly those interpreted as 2+, 
      would benefit from FISH to more accurately assess HER-2/neu status and avoid 
      inaccurate prognostication and inappropriate treatment.
FAU - Kakar, S
AU  - Kakar S
AD  - Department of Pathology, University of Illinois at Chicago, Chicago, IL 60612, 
      USA.
FAU - Puangsuvan, N
AU  - Puangsuvan N
FAU - Stevens, J M
AU  - Stevens JM
FAU - Serenas, R
AU  - Serenas R
FAU - Mangan, G
AU  - Mangan G
FAU - Sahai, S
AU  - Sahai S
FAU - Mihalov, M L
AU  - Mihalov ML
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Mol Diagn
JT  - Molecular diagnosis : a journal devoted to the understanding of human disease 
      through the clinical application of molecular biology
JID - 9614965
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Reagent Kits, Diagnostic)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - Mol Diagn. 2000 Sep;5(3):191-2. PMID: 11186126
MH  - Breast Neoplasms/*diagnosis/genetics/metabolism/mortality
MH  - Carcinoma/*diagnosis/genetics/metabolism/mortality
MH  - Cell Nucleus/ultrastructure
MH  - DNA, Neoplasm/*analysis
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry/economics/*standards
MH  - In Situ Hybridization, Fluorescence/economics/*standards
MH  - Prognosis
MH  - Reagent Kits, Diagnostic
MH  - Receptor, ErbB-2/*genetics/immunology/*metabolism
MH  - *Survival Rate
EDAT- 2000/11/09 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/09 11:00
PHST- 2000/11/09 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/09 11:00 [entrez]
AID - S1084-8592(00)70774-0 [pii]
AID - 10.1054/modi.2000.16690 [doi]
PST - ppublish
SO  - Mol Diagn. 2000 Sep;5(3):199-207. doi: 10.1054/modi.2000.16690.